Wall Street analyst price targets, ratings consensus & upside potential
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Puma Biotechnology, Inc. (PBYI) has a Wall Street consensus price target of N/A, based on estimates from 19 covering analysts. The company has a market capitalization of $287M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PBYI trades at a trailing P/E of 9.3x and forward P/E of 22.8x. Analysts expect EPS to grow -58.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.10, with bear and bull scenarios of $1227.73 and $-36.17 respectively. Model confidence stands at 32/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PBYI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for PBYI is $N/A, close to the current price of $5.7 (N/A% implied move). Based on 19 analyst estimates, the stock appears fairly valued near current levels.
PBYI has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
PBYI trades at a forward P/E of 22.8x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $N/A for PBYI, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $-36 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PBYI is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 7 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PBYI stock forecast based on 19 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $1228/$-36.
Our quantitative valuation model calculates PBYI's fair value at $6 (base case), with a bear case of $1228 and bull case of $-36. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 32/100.
PBYI trades at a forward P/E ratio of 22.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 9.3x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
PBYI appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PBYI analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $1228-$-36 range provides an independent fundamental perspective.